UK markets open in 7 hours 29 minutes
NIKKEI 225
38,229.11 -44.99 (-0.12%) HANG SENG
18,963.68 +487.78 (+2.64%) CRUDE OIL
78.05 -0.21 (-0.27%) GOLD FUTURES
2,368.10 -6.90 (-0.29%) DOW
39,512.84 +837.14 (+2.16%) Bitcoin GBP
49,004.05 +336.30 (+0.69%)
Zevra Therapeutics, Inc. (ZVRA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 201.72M |
| Enterprise value | 177.75M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 6.22 |
| Price/book (mrq) | 3.26 |
| Enterprise value/revenue | 7.92 |
| Enterprise value/EBITDA | -2.02 |
Trading information
Stock price history
| Beta (5Y monthly) | 1.87 |
| 52-week change 3 | 10.55% |
| S&P500 52-week change 3 | 26.27% |
| 52-week high 3 | 7.2800 |
| 52-week low 3 | 3.8900 |
| 50-day moving average 3 | 5.3056 |
| 200-day moving average 3 | 5.2276 |
Share statistics
| Avg vol (3-month) 3 | 251.26k |
| Avg vol (10-day) 3 | 198.97k |
| Shares outstanding 5 | 41.85M |
| Implied shares outstanding 6 | 43.67M |
| Float 8 | 36.09M |
| % held by insiders 1 | 8.39% |
| % held by institutions 1 | 30.86% |
| Shares short (30 Apr 2024) 4 | 2.65M |
| Short ratio (30 Apr 2024) 4 | 11.39 |
| Short % of float (30 Apr 2024) 4 | 6.37% |
| Short % of shares outstanding (30 Apr 2024) 4 | 6.34% |
| Shares short (prior month 28 Mar 2024) 4 | 2.25M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | 28 Dec 2020 |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:16 |
| Last split date 3 | 28 Dec 2020 |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | -178.47% |
| Operating margin (ttm) | -598.13% |
Management effectiveness
| Return on assets (ttm) | -27.75% |
| Return on equity (ttm) | -82.27% |
Income statement
| Revenue (ttm) | 27.71M |
| Revenue per share (ttm) | 0.74 |
| Quarterly revenue growth (yoy) | 19.00% |
| Gross profit (ttm) | N/A |
| EBITDA | -56.08M |
| Net income avi to common (ttm) | -49.45M |
| Diluted EPS (ttm) | -1.3000 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 52.72M |
| Total cash per share (mrq) | 1.26 |
| Total debt (mrq) | 44.29M |
| Total debt/equity (mrq) | 90.72% |
| Current ratio (mrq) | 2.10 |
| Book value per share (mrq) | 1.17 |
Cash flow statement
| Operating cash flow (ttm) | N/A |
| Levered free cash flow (ttm) | N/A |
© 2024 Yahoo. All rights reserved.